Results of Operations and Financial Condition. On August 5, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter ended June 30, 2026, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, August 5, 2026, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibi…

Results of Operations and Financial Condition. On May 6, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the first quarter ended March 31, 2026, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, May 6, 2026, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.1…

Entry into a Material Definitive Agreement. On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW (the “Litigation”) related to claims arising under the Colla…

Termination of a Material Definitive Agreement. On March 12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”). The Credit Agreement provided for a senior secured loan facility in an aggregate prin…

Results of Operations and Financial Condition. On March 9, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the fourth quarter ended December 31, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Monday, March 9, 2026, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit…

Chief Financial Officer and Treasurer — Justin Renz: The company appointed Justin Renz as Chief Financial Officer and Treasurer.

interim principal financial officer — Timothy Sangiovanni: Mr. Timothy Sangiovanni was appointed as interim principal financial officer.

Director — Wendy Dixon: Dr. Wendy Dixon resigned from the Board and each committee of the Board.

Chief Financial Officer and Treasurer — R. LaDuane Clifton: Resigned to pursue other professional opportunities.

Results of Operations and Financial Condition. On November 5, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the third quarter ended September 30, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, November 5, 2025, at 4:30 p.m. ET. A copy of the press release is furnished a…

Results of Operations and Financial Condition. On August 12, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter ended June 30, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, August 12, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibi…

Results of Operations and Financial Condition . On May 13, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the first quarter ended March 31, 2025, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, May 13, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhibit 99.…

Results of Operations and Financial Condition. On April 7, 2025, the Company issued a press release in relation to the Asset Sale, in which the Company announced that as of March 31, 2025, the Company’s cash, cash equivalents and investments were approximately $68.7 million. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in this item, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section…

Other Events. As noted above, on April 7, 2025, the Company announced that as of March 31, 2025, the Company’s cash, cash equivalents and investments were approximately $68.7 million. The foregoing cash, cash equivalents and investments information provided in this Current Report on Form 8-K is based on preliminary unaudited information and management estimates for the quarter ended March 31, 2025, is not a comprehensive statement of the Company’s financial results as of and for the fiscal qu…

Completion of Acquisition or Disposition of Assets. On April 1, 2025, Zevra Therapeutics, Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The Company was awarded the voucher under a U.S. Food and Drug Administration (“FDA”) program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV when MIPLYFFA (arimoclomol) was ap…

Results of Operations and Financial Condition . On March 11, 2025, Zevra Therapeutics, Inc., a Delaware corporation (the "Company" or "Zevra"), issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024, as well as information regarding a conference call and live audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, March 11, 2025, at 4:30 p.m. ET. A copy of the press release is furnished as Exhi…

Entry into a Material Definitive Agreement On February 26, 2025, Zevra Therapeutics, Inc. (the “Company”) and Zevra Denmark A/S entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to the buyer. The Company was awarded the voucher under a U.S. Food and Drug Administration (“FDA”) program intended to encourage the development of certain rare pediatric disease product applic…

Chief Development Officer — Christal M.M. Mickle: Ms. Mickle was notified that she would no longer serve as Chief Development Officer.

above, on November 21, 2024, the Company announced that MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense. The Company is utilizing its comprehensive patient support program, AmplifyAssist™, to support the individual needs of eligible patients and those who care for them. Available resources include personalized insurance coverage education and support, copay and alternate funding identification assistance for e…

Results of Operations and Financial Condition . On November 12, 2024, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the third quarter ended September 30, 2024, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, November 12, 2024, at 4:30 p.m. ET. A copy of the press release is furnished…

above, on September 20, 2024, the Company announced that the FDA approved MIPLYFFA capsules as an orally delivered treatment for NPC. In addition, the Company announced that it has received a rare pediatric disease priority review voucher in conjunction with the approval. Caution Concerning Forward-Looking Statements This Current Report on Form 8-K may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements incl…

Results of Operations and Financial Condition . On August 13, 2024, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter ended June 30, 2024, as well as information regarding a conference call and live audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, August 13, 2024, at 4:30 p.m. ET. A copy of the press release is furnished as…

Other Events. On August 8, 2024, Zevra Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the offering, issuance and sale by the Company of 9,230,770 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a public offering pr…

is based on preliminary unaudited information and management estimates, is not part of a comprehensive statement of the Company’s financial results for any completed period, and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not completed its review of this preliminary financial information. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning o…

above, on August 2, 2024, the Company announced that the FDA GeMDAC voted favorably (11 yes, 5 no) that the data support that arimoclomol is effective in the treatment of patients with NPC. The GeMDAC, which consists of experts in the fields of medical genetics, inborn errors of metabolism, epidemiology and other related specialties, discussed the benefits and risks of arimoclomol, including the data recently presented at the 45 th Annual Meeting of the Society for Inherited Metabolic Disorde…